Allergic Rhinitis

The Allergen BioCube™ (ABC) is a "next generation" environmental exposure unit that has been specifically designed to better study the epidemiology and pathophysiology of allergic rhinitis and rhinoconjunctivitis.

High Environmental Correlation
because the allergen exposure mimics environmental conditions
Tight controls
via a smaller chamber that allows for the more precise matching of allergen levels to subjects’ sensitivities
Objective and subjective measurements
including our Nasal Inflammation Scale (NIS), which helps to reduce subject bias
Paul Gomes, MS

Paul Gomes, MS
Vice President of Allergy Research
BY THE NUMBERS
12,000

The number of qualified allergy subjects that Ora can immediately access through its global OraNet site network.Learn more about our Allergy Team.>>

Ora's new Allergen BioCube™ (ABC) is a "next generation" environmental exposure unit that has been specifically designed to better study the epidemiology and pathophysiology of allergic rhinitis and rhinoconjunctivitis.

The ABC explores multiple allergen exposure, thus more accurately reflecting the clinical condition Pretreatment: Allergen BioCube™ Allows Priming with Alternate Seasonal or Perennial Allergens prior to test exposures Combined Exposures: Supports simultaneous controlled administration of multiple pollens Ora has been built upon decades of the highest quality standards and scientific rigor. Our ability to navigate away from clinical trial risks has enabled us to gain respect among large pharmaceutical companies and regulatory authorities alike.

Ora's quality of clinical trial execution is unparalleled. We understand that our reputation and our performance will translate into your success. That is why, for each allergy trial, we provide highly trained staff at every site who maintain the highest level of regulatory compliance.

Learn more about our Allergen BioCube™ Chamber Model